Article
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Cell - 22 Jul 2021
Copin Richard, Baum Alina, Wloga Elzbieta, Pascal Kristen E, Giordano Stephanie, Fulton Benjamin O, Zhou Anbo, Negron Nicole, Lanza Kathryn, Chan Newton, Coppola Angel, Chiu Joyce, Ni Min, Wei Yi, Atwal Gurinder S, Hernandez Annabel Romero, Saotome Kei, Zhou Yi, Franklin Matthew C, Hooper Andrea T, McCarthy Shane, Hamon Sara, Hamilton Jennifer D, Staples Hilary M, Alfson Kendra, Carrion Ricardo, Ali Shazia, Norton Thomas, Somersan-Karakaya Selin, Sivapalasingam Sumathi, Herman Gary A, Weinreich David M, Lipsich Leah, Stahl Neil, Murphy Andrew J, Yancopoulos George D, Kyratsous Christos A
Abstract excerpt
Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
